Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 500-509

  Tian, Erming ^a   Landowski, Terry H ^b   Stephens, Owen W ^a   Yaccoby, Shmuel ^a   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 DIMETHYLAMINOETHOXY ELLIPTICINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; DOXORUBICIN; ELLIPTICINE DERIVATIVE; MELPHALAN; MESSENGER RNA; NSC 338258; PROTEIN; PROTEIN CKS1B; UNCLASSIFIED DRUG;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASES; ELLIPTICINES; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA;

EID: 41649084957     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0524     Document Type: Article

References (31)

1. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
2. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-25.
3. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
4. Sawyer JR, Tricot G, Lukacs JL, et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 2005;42:95-106.
5. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood 2006;108:1724-32.
6. Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA. COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. J Mol Graph Model 2002;20:297-30.
7. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
8. Holbeck SL, Update on NCI in vitro drug screen utilities. Eur J Cancer 2004;40:785-93.
9. Sausville EA, Holbeck SL. Transcription profiling of gene expression in drug discovery and development: the NCI experience. Eur J Cancer 2004;40:2544-9.
10. Scherf U, Ross DT, Waltham M. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
11. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
12. Dalton LK, Demerac S, Elmes BC, Loder JW, Swan JM, Tertei T. Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4,3-b]carbazoles. Aust J Chem 1967;20:2715-27.
13. Bhuyan BK, Fraser TJ, Li LH. Cell cycle phase specificity and biochemical effects of ellipticine on mammalian cells. Cancer Res 1972;32:2538-44.
14. Multon E, Riou JF, LeFevre D, Ahomadegbe JC, Riou G, Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417. Biochem Pharmacol 1989;38:2077-86.
15. Stiborová M, Sejbal J, Boek-Dohalská L, et al. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res 2004;64:8374-80.
16. Larsen AK, Jacquemin-Sablon A. Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxyellipticine. Cancer Res 1989;49:7115-9.
17. Dereuddre S, Delaporte C, Jacquemin-Sablon A. Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 1997;57:4301-8.
18. Vendôme J, Letard S, Martin F. Molecular modeling of wild-type and D816V c-kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 2005;48:6194-201.
19. Huang Y, Blower PE, Yang C, et al. Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1. Pharmacogenomics J 2005;5:112-25.
20. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
21. Hazlehurst LA, Foley NE, Gleason-Guzman MC, et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res 1999;59:1021-8.
22. Chen D, Yang H, Wang G, et al. Electron microscopic study of the morphology and morphogenesis of virus of hemorrhagic fever with renal syndrome. J Electron Microsc Tech 2005;7:111-7.
23. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 1998;26:597-603.
24. Cheung W, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001;15:264-71.
25. Shaughnessy JD. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10:117-26.
26. Sureau F, Moreau F, Millot JM, et al. Microspectrofluorometry of the protonation state of ellipticine, an antitumor alkaloid, in single cells. Biophys J 1993;65:1767-74.
27. Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain-reaction analysis of MDR1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993;213:414-21.
28. Yanamandra N, Colaco N, Parquet N, et al Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 2006;12:591-9.
29. Kuehl M, Bergsagel P. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
30. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
31. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;27:165-72.